Protective effect of mepacrine on hypoxia-reoxygenation-induced acute lung injury in rats.
Mepacrine, a cell membrane stabilizer and inhibitor of phospholipase A2 (PLA2), exerts a protective effect on ischemia-reperfusion injury in heart; however, its effect in lungs has not been examined. This study aimed to determine whether mepacrine pretreatment attenuates ischemia-reperfusion lung injury simulated by hypoxia reoxygenation and to identify possible mechanisms for such protection. Acute lung injury was induced in Sprague-Dawley rats by ventilation with 5% CO2-95% N2 and 5% CO2-95% air. Pretreatment with 0.06 mM mepacrine significantly attenuated the acute lung injury. Capillary filtration coefficient, lung weight gain, and protein concentration of lung lavage fluid were significantly lower in mepacrine-treated rats than in rats exposed to hypoxia reoxygenation alone. Steroid dexamethasone, another potential PLA2 inhibitor, had almost no protective effect. Mepacrine but not dexamethasone caused dose-dependent attenuation of the increase in leukocyte chemiluminescence produced by exposure to phorbol myristate acetate. Mepacrine also dose-dependently inhibited production of tumor necrosis factor-alpha (TNF-alpha) by human monocytes; dexamethasone was much less effective in decreasing TNF-alpha production. We conclude that mepacrine but not dexamethasone can significantly attenuate a hypoxia-reoxygenation-induced injury of the lung. This protective effect of mepacrine may not be the result of its inhibition of PLA2 but rather of its downregulation of oxygen radical production by circulating or resident leukocytes or its attenuation of TNF-alpha production by macrophages.
Shen
C Y
CY
Department of Medicine, Tri-Service General Hospital, Taiwan, Republic of China.
Wang
D
D
Chang
M L
ML
Hsu
K
K
D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology; D003907:Dexamethasone / Q000494:pharmacology; D006098:Granulocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D000860:Hypoxia / Q000503:physiopathology*; D066298:In Vitro Techniques; D007958:Leukocyte Count; D008171:Lung Diseases / Q000503:physiopathology / Q000517:prevention & control*; D009929:Organ Size / Q000187:drug effects / Q000502:physiology; D010477:Perfusion; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D011652:Pulmonary Circulation / Q000502:physiology*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects / Q000502:physiology; D011796:Quinacrine / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology
D014409:Tumor Necrosis Factor-alpha; D003907:Dexamethasone; D010741:Phospholipases A; D054467:Phospholipases A2; D011796:Quinacrine